Scil Proteins bags Ubags for COO
This article was originally published in Scrip
Scil Proteins, a private biotech company specialising in the research, development and production of recombinant proteins, has appointed Frank Ubags chief operating officer. Previously, Mr Ubags was Scil Proteins' chief financial officer, having held that position for the past three years. Melanie Käsmarker will take over the responsibility of the firm's finance, procurement and human resource departments as director of finance. She has served the company for the past three years as head of controlling and accounting.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.